DR. AHLUWALIA JOINS EXECUTIVE COMMITTEE
The Caris Precision Oncology Alliance Executive Committee is proud to announce its newest member, Dr. Manmeet Ahluwalia, MD, MBA. Regarded as one of the leading neuro-oncologists in the world, Dr. Ahluwalia is currently the Chief of Medical Oncology, Deputy Director, and Chief Scientific Officer at the Miami Cancer Institute (MCI). He joined MCI in 2021 after working at the Cleveland Clinic as Dean and Diane Miller Family Endowed Chair in Neuro-Oncology and the Head of Operations in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. Dr. Ahluwalia’s primary areas of research and patient care are primary tumors and brain metastases with additional interests in drug development for complex cancers. Read more.
CARIS POA WELCOMES THREE NEW MEMBERS
Three new members have recently joined the Caris POA: Oklahoma University Health Stephenson Cancer Center, the Medical College of Wisconsin, and the Northside Hospital Cancer Institute. With the addition of each new member, our goal of building the foremost precision medicine focused research network in the world becomes that much closer. We continue to bring together the brightest minds in academic research, community care and clinical R&D to deliver greater molecular science solutions in an effort to improve the lives of cancer patients. To view the press release of each new member, please click on any of the links below:
The OU Health Stephenson Cancer Center is the state’s only National Cancer Institute (NCI)-Designated Cancer Center, providing a critical resource… (Read more).
The Medical College of Wisconsin (MCW) is the largest private research institution in Wisconsin, assisting communities… (Read more).
Northside Hospital Cancer Institute (NHCI) has been offering cancer care services in Georgia since 1978, and in that time has grown into one of the largest… (Read more).
NINE STUDIES PRESENTED BY CARIS POA AT ESMO 2022
At this year’s ESMO Congress, Caris Life Sciences® (Caris), and its partners within the Caris Precision Oncology Alliance (POA) presented nine studies covering a diversity of tumor types and genomic alterations. The findings demonstrate clinical benefits of Caris’ whole exome and whole transcriptome approach to molecular profiling. “The depth and range of research being presented by Caris and the POA demonstrates the value this collaboration brings to the broader oncology community,” said Chadi Nabhan, MD, MBA,FACP, Chairman of the POA. “The study findings provide critical insights into cancer biology and treatment outcomes that will help drive further clinical research and better inform diagnoses, clinical and therapeutic decision-making for oncology practices.” If you would like to view or download a copy of this year’s Caris Abstracts and Presentation Schedule at ESMO, please click here.
REDESIGNED CARIS POA PUBLICATION REPOSITORY
One of the main pillars of the Caris Precision Oncology Alliance (POA) has always been collaboration. With over 500 investigator-initiated publications produced to date, we continue to optimize big data, AI, and machine learning through our research to improve the outcomes for our patients. This summer the POA publication repository was enhanced to make searching more efficient and user-friendly for our members. With a new menu and updated content, publications can be narrowed down by publication type, tumor type, biomarker (150+), and POA institution. The complete list of POA publications can be found here and we encourage all of our members to use it.